Previous 10 | Next 10 |
Vertigo3d/E+ via Getty Images Space flights and earnings reports dominated market coverage on Tuesday. Amazon (AMZN) founder Jeff Bezos took his first trip past the outer atmosphere. Meanwhile, a host of companies released their quarterly results. Virgin Galactic (SPCE) took a dip in Tuesday'...
NeuroBo Pharmaceuticals (NRBO) +36%.Immunome (IMNM) +29% rallies 31% after antibody cocktail neutralizes Delta variant in pre-clinical testingMediWound (MDWD) +19% announces positive topline results from Phase 3 pediatric ctudy (CIDS) of nexoBrid for eschar removal of seve...
Lantern Pharma (LTRN) has added ~15.8% in early trading after the company announced that its drug candidate, LP-184 led to more than 90% of pancreatic tumor shrinkage in mice after eight weeks of therapy.In contrast, the tumors in untreated mouse models grew more than 11 t...
Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184 - LP-184 is a next-generation DNA-damaging agent being developed for pancreatic cancer in a collaboration with Fox Chase Cancer Center - LP-184 has demonstrated sig...
Lantern owns an AI drug development platform called RADR that increases in value each day as it analyzes more data points. Using this platform, Lantern has generated an impressive internal pipeline of several different drugs including LP-100, LP-300, LP-184, and LP-284. In late 20...
The following slide deck was published by Lantern Pharma Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Lantern Pharma Inc. 2021 Q1 - Results - Earnings Call Presentation
Lantern Pharma Inc. (LTRN) Q1 2021 Earnings Conference Call May 3, 2021 04:30 p.m. ET Company Representatives Panna Sharma - President, Chief Executive Officer David Margrave - Chief Financial Officer Dr. Kerry Barnhart - Vice President of Clinical Development Marek Ciszewski - Investor Relat...
Lantern Pharma (LTRN): Q1 GAAP EPS of -$0.24.Cash and cash equivalents were $81.4M as of March 31, 2021 compared to $19.2M as of December 31, 2020.Press release. For further details see: Lantern Pharma reports Q1 results
Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights - RADR® A.I. platform surpasses 4.6 billion datapoints curated for oncology drug development across a wide a range of tumors and drug classes - Phase 2 clinical trial for non-smokers ...
Point Roberts, WA and Vancouver, BC - May 3, 2021 (Investorideas.com Newswire) Investorideas.com ( www.investorideas.com ), a global investor news source covering Artificial Intelligence (AI) brings you today's edition of The AI Eye - watching stock news, deal tracker and advancemen...
News, Short Squeeze, Breakout and More Instantly...
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement towards the development of a diagn...
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brou...
Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% ...